June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Early and delayed visual acuity responders to ranibizumab in patients with neovascular age-related macular degeneration: a retrospective pooled analysis from the real-world LUMIERE and TWIN studies
Author Affiliations & Notes
  • jean paul bellamy
    Clinique sainte jeanne d'arc, Saint Brieuc, France
  • Gérard Mimoun
    Centre ophtalmologique de l’école militaire, Paris, France
  • Eric H Souied
    Ophthalmology, Centre Hospitalier Intercommunal, Creteil, France
  • Hassiba Oubraham
    Ophthalmogist private office Montargis, Montargis, France
  • Catherine Français
    Ophtalmology, Centre de l'Odéon, Paris, France
  • Franck Rumen
    Visiopôle, Lagord, France
  • Marie-Laure Lelez
    Ophtalmology, CHU Tours, Tours, France
  • Elisabeth Hermouet
    Ophtalmology, Clinique Sourdille, Nantes, France
  • Laetitia Finzi
    Ophtalmology Division, Novartis Pharma S.A.S, Reuil-Malmaison, France
  • Salomon Y Cohen
    Centre d'Imagerie et de Laser, Paris, France
  • Footnotes
    Commercial Relationships jean paul bellamy, None; Gérard Mimoun, None; Eric Souied, Allergan (C), Bayer (C), Novartis Pharma S.A.S (C), Thea (C); Hassiba Oubraham, Allergan (C), Bayer (C), Novartis Pharma S.A.S (C); Catherine Français, Bayer (C), Novartis Pharma S.A.S (C), Roche (C); Franck Rumen, Bayer (C), Novartis Pharma S.A.S (C); Marie-Laure Lelez, None; Elisabeth Hermouet, Bayer (C), Novartis Pharma S.A.S (C); Laetitia Finzi, Novartis Pharma S.A.S (E); Salomon Cohen, Alcon (C), Allergan (C), Bayer (C), Novartis Pharma S.A.S (C), Thea (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2823. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      jean paul bellamy, Gérard Mimoun, Eric H Souied, Hassiba Oubraham, Catherine Français, Franck Rumen, Marie-Laure Lelez, Elisabeth Hermouet, Laetitia Finzi, Salomon Y Cohen; Early and delayed visual acuity responders to ranibizumab in patients with neovascular age-related macular degeneration: a retrospective pooled analysis from the real-world LUMIERE and TWIN studies. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2823.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

In clinical trials, the proportion of early ≥15 letter gainers at Month 3 ranged from 18% to 29% with ranibizumab treatment in patients with neovascular age-related macular degeneration (nAMD). A retrospective pooled analysis from the LUMIERE and TWIN studies aimed to identify the early and delayed visual acuity (VA) responders, and the possible predictors of response to ranibizumab treatment in real-world practice in nAMD.

 
Methods
 

LUMIERE and TWIN were 12 month, retrospective purely observational studies conducted in clinical settings to evaluate the functional and morphological outcomes with ranibizumab treatment in patients with nAMD. The analyzed population (N=401) consisted of patients who received a loading phase with 3 monthly ranibizumab injections and had at least one VA assessment one month after the third injection. Based on the treatment’s response, patients were categorized as 'early responders' (gain of ≥15 letters at Month 3 from baseline) or ‘delayed responders' (did not gain ≥15 letters at Month 3 but did at Month 12 from baseline). The evaluation included proportions of 'early responders' and ‘delayed responders', and comparisons of 'early responders' vs ‘delayed responders', and comparisons of the two groups accordingly to their baseline characteristics.

 
Results
 

Overall, 18.9% (76/401) patients were early responders. Of the 325 who were not categorized as early responders, 10.5% (34/325) were delayed responders. At baseline, the mean VA for early responders was significantly lower compared to delayed responders (40.4 vs 51.6 letters, p<0.001). The two groups presented mostly occult choroidal neovascularization at baseline (59.7% and 50%) and 30.3% of early responders and 44.1% of delayed responders were reported with vascularized pigment epithelium detachment (Table 1).

 
Conclusions
 

This retrospective pooled analysis from LUMIERE and TWIN studies suggests that maintaining ranibizumab treatment can result in VA improvements in the subgroup of delayed responders. These “real-world” data are in agreement with those of clinical trials, indicating that ranibizumab in real-word wAMD patients receiving the loading phase is as effective as in clinical trials.  

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×